Yali Ding

Yali Ding, PhD is an Assistant Professor in the Department of Pediatrics specializing in molecular mechanisms of leukemia. Her research bridges basic science and translational oncology with focus on high-risk hematopoietic malignancies.

Her primary research interests include:

• Casein Kinase 2 (CK2) signaling pathways in leukemia pathogenesis
• Transcriptional regulation by IKAROS and associated factors
• Chromatin remodeling in T-cell acute lymphoblastic leukemia
• Development of targeted therapies for high-risk leukemias
• Mechanisms of therapeutic resistance in acute leukemias

Analysis of Dr. Ding's recent publications (2021-2025) reveals a cohesive research program centered on CK2's role across leukemia subtypes. Her work demonstrates how CK2 inhibition (e.g., CX-4945) disrupts critical pathways in AML while investigating dual-targeting strategies for B-ALL. A significant portion examines IKAROS-mediated transcriptional networks in T-ALL heterochromatin regulation, connecting epigenetic mechanisms to tumor suppression. Her publications span high-impact journals like Leukemia and Cancers, with increasing output volume indicating growing research momentum.

With an h-index of 14 and 553 Scopus citations, Dr. Ding has established a productive research trajectory evidenced by 25 total publications since 2008. Her work contributes to UN Sustainable Development Goals related to good health, particularly through mechanistic studies of leukemia pathogenesis and therapeutic development.